Showing 1216 Results
2023 Annual Report
In 2023, NPC conducted policy-relevant research and analysis to foster evidence-based health policy discussions and decision-making. Learn more in our Annual Report.
New Research Finds Patient Access to Drugs Selected for IRA Is Often High (JAMA Health Forum)
A review of Medicare Part D coverage for 10 drugs in the Medicare Drug Price Negotiation Program raises concerns about how program implementation may impact patient access.
Medicare Part D Coverage of Drugs Selected for the Drug Price Negotiation Program
Published in JAMA Health Forum, this study examined current Medicare beneficiary access to the drugs selected for the first round of the Inflation Reduction Act’s Medicare Drug Price Negotiation…
NPC Comments Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights
NPC submitted comments to the National Institute of Standards and Technology in response to the Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise…
Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications
The Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program (DPNP) may lead to fewer subsequent indications and delay launches for small molecule drugs, according to new research from…
NPC Releases Updated Guiding Practices to Improve Patient-Centricity in Value Assessments
The Guiding Practices include 33 specific recommendations to ensure value assessments account for the full value pharmaceuticals provide to patients and society
Guiding Practices for Patient-Centered Value Assessment (2024)
NPC has updated its Guiding Practices for Patient-Centered Value Assessment. This update of NPC's guiding practices for US value assessment will help inform the growing importance of this tool to…
NPC Comments on HHS Notice of Benefit and Payment Parameters for 2025
In this comment letter, NPC offers input on HHS' Notice of Benefit and Payment Parameters for 2025, annual rulemaking that governs programs and health plans offered under the Affordable Care Act.
NPC Submits Comments to CMS on Proposed Changes to Medicare Programs
In this comment letter, NPC weighs in on CMS' proposed technical and policy changes to Medicare Advantage and other Medicare programs.
ICER’s UPI Report: Unsupported Policy Information
The 2023 iteration of ICER's Unsupported Price Increase report is misguided at best and harmful to patients and society at worst. NPC outlines why the report should not be used to determine policy or…
Global Experts Highlight Concerns With Implementation of IRA-Mandated Medicare Drug Price Negotiation Program
Value in Health highlights commentary contributed by NPC's John O'Brien and NPC board member Jan E. Hansen on the implications of the Medicare Drug Price Negotiation Program.
Three Takeaways from CMS's Patient-Focused Listening Sessions: Toward Improved Patient Engagement
CMS hosted patient-focused listening sessions to discuss the first 10 drugs selected for the Medicare Drug Price Negotiation Program. In this analysis, NPC offers three takeaways to inform how the…
New Analysis Shows IRA May Lead to Delayed Launches, Fewer Subsequent Indications, and Less Evidence Generation
NPC writes in Health Affairs Forefront about the unintended consequences of the IRA and the impact of the changing economic incentives for clinical development programs.
